EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Herczeg A, Türk D, Hegedűs Z, Svajda L, Rásó E, Ladányi A, Csikó KG, Kenessey I, Szöőr Á, Vereb G, Remenár É, Tóvári J.
Cserepes M, et al. Among authors: raso e.
Cancers (Basel). 2022 May 13;14(10):2407. doi: 10.3390/cancers14102407.
Cancers (Basel). 2022.
PMID: 35626010
Free PMC article.